MBRX News and Press, Moleculin Biotech Inc. From 12/03/20

Palm Beach, FL – December 3, 2020 – Acute myeloid leukemia (AML) is a rare and heterogeneous blood cancer with a poor overall prognosis. It affects predominantly older adults with a median age at diagnosis of 66 years but also includes about 15% of children from birth to 19 ye...

Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference HOUSTON , Dec. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pha...

Moleculin Biotech (MBRX) soars 41% in premarket, after the FDA has designated Rare Pediatric Disease tag for its drug candidate WP1066, for each of three indications, including diffuse intrinsic pontine glioma, medulloblastoma and atypical teratoid rhabdoid tumor, all are types...

Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066 Priority Review Vouchers subject to approved NDA PR Newswire HOUSTON, Dec. 1, 2020 HOUSTON , Dec. 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Molec...

Palm Beach, FL – November 19, 2020 – According to the American Cancer Society, the number of new acute myeloid leukemia cases is estimated to continue to grow in the U.S. due to a number of factors.  The rising prevalence of acute myeloid leukemia and unmet needs of the p...

Moleculin Biotech (MBRX) has announced additional preclinical data, demonstrating improved activity with liposomal annamycin against acute myeloid leukemia ((AML)) when used in combination with the commonly used antileukemic drug Ara-C (also referred to as cytarabine) versus single agent...

Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML Experimental data to be presented at American Society for Hematology Annual Conference PR Newswire HOUSTON, Nov. 19, 2020 HOUSTON , Nov. 19,...

Moleculin Biotech (MBRX): Q3 GAAP EPS of -$0.06 beats by $0.04.Cash and cash equivalents of $12.8M.Press Release For further details see: Moleculin Biotech EPS beats by $0.04

Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020 PR Newswire HOUSTON, Nov. 13, 2020 HOUSTON , Nov. 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pha...

Moleculin Biotech (MBRX) inks agreement with the University of Campinas in São Paulo, Brazil to further enable collaboration into its research on the anti-viral capabilities of its drug candidate WP1122, specifically for the coronavirus. Recently the University of Campinas published inde...